The Cleaner XT™ Device as an Endovascular Adjunct for Pharmacomechanical Thrombolysis of Thrombosed Arteriovenous Fistulas and Grafts

Khian Wan Sarah Joy Huan, MBBS (Singapore), MRCS(Ed),1 Chieh Suai Tan, MBBS (Singapore), MRCP (UK),2 Deborah Chua, MB BCh BAO (Hons),1 Charyl Jia Qi Yap, BSc,1 Ru Yu Tan, MBBS (Malaysia), MRCP (UK),2 Tze Tec Chong, MBBS, FACS, RPVI,1 and Tjun Yip Tang, MB BChir, MA (Cantab), FRCS (Glas), FRCS (Eng), MD (Vascular Surg, Cambridge), FAMS1,3

Objective: This paper documents our experience using the Cleaner XT™ device (Argon Medical Devices, Plano, TX, USA) for pharmacomechanical thrombolysis (PMT) of thrombosed haemodialysis arteriovenous grafts (AVG) and fistulas (AVF).

Materials and Methods: This was a retrospective case series (n=17) over six months at Singapore General Hospital. We evaluated demographics, procedural data, technical and procedural success, patency rates and complications.

Results: There were 8 (47%) males and the patients’ mean age was 66 (± 5.7) years. The mean age of AVF/AVG was 1605 (± 1099) days. All procedures were performed under local anaesthetic. PMT was performed within a mean time of 40 (±34.3) hours from the presentation. Technical, clinical and procedural success was 15/17 (88%). The thrombolysis agents used were tissue plasminogen activator (52.9%) and urokinase (41.2%). Mean primary patency time was 114 (± 116) days, with a 65% 1-month and 47% 3-month primary patency rates. The mean secondary patency time was 155 (±132) days, with 76% one-month and 65% three-month secondary patency rates, respectively. AVF rupture occurred in 3/17 (18%) cases but did not involve loss of the access circuit.

Conclusion: The Cleaner XT™ device is a safe, minimally invasive endovascular tool for PMT in thrombosed AVF/AVG, with relatively high success and low complication rates.

Keywords: CDT, thrombolysis, Cleaner XT™, primary patency, AVF

Introduction

Haemodialysis can be performed via an arteriovenous fistula (AVF) or arteriovenous graft (AVG). These procedures can be prone to thrombosis because of progressive narrowing from neo-intimal hyperplasia and repeated trauma from cannulation, leading to loss of access if left untreated. This failure leads to significant morbidity and mortality in patients on hemodialysis.1) The vascular access should be declotted promptly to avoid thrombus solidification and consequent loss of the arteriovenous access circuit.2) This can be performed either through an open surgical or endovascular percutaneous thrombectomy. The latter is associated with lower morbidity and mortality as well as faster recovery, which is especially important in end-stage renal disease (ESRD) patients with multiple co-morbidities.3) Various endovascular techniques have been described, including catheter-directed thrombolysis (CDT) and mechanical thrombectomy. Such techniques are often employed in conjunction with treating the underlying pathology, usually stenosis, by balloon angioplasty.4) Pharmacomechanical thrombolysis (PMT) was developed as a means of combining open and endovascular approaches with direct removal of a clot and adjunctive thrombolysis, achieving complete clot resolution with reduced thrombolytic dose, cost and treatment time.5) PMT is an effective technique comparable to surgi-
Clinical thrombectomy for treating thrombosis in AVF and AVG. Furthermore, its outcomes were comparable to that of CDT in deep vein thromboses in terms of patency rate, with a shorter length of stay, leading to lower costs. There are a range of PMT devices available, with different mechanisms of action, broadly divided into two categories.

1. Hydrodynamic recirculation devices. The mechanism is based on the Venturi effect produced by high-speed saline jets, where the thrombus is sucked into the device and macerated. The products are then removed by an exhaust lumen in the device. An example would be the Angiojet Rheolytic System (Boston Scientific, Marlborough, MA, USA). This device has a 360-degree suction vortex, which may reduce the number of passes and the need for rotational positioning. It also functions isovolumetrically, which minimises the risk of unintentional hypovolemia during declotting.

2. Rotational recirculation devices. The clot is fragmented via generation of a hydrodynamic vortex, which is created by a high-speed rotating impeller or basket. An example would be the Arrow–Trerotola percutaneous thrombectomy device (Teleflex, Wayne, PA, USA), which is simple and inexpensive to manufacture but causes significant endothelial denudation in native vessels.

This study documents our experience using the Cleaner XT™ Rotational Thrombectomy System (Argon Medical Devices, Plano, TX, USA) for PMT of thrombosed AVG and AVF. We looked at its safety, efficacy and complications as well as the procedural tips we learnt from using the device.

Materials and Methods

Patient cohort

This is an investigator-initiated pilot single centre, single- arm retrospective case series study over six months (Dec 2018–July 2019) at Singapore General Hospital (SGH). The local Human Research Ethics Committee approved this study (CIRB ref: 2018/2557). SGH is the oldest restructured government hospital, situated in central Singapore and performs over 3000 AVG or AVF salvage procedures annually.

We used the Cleaner XT™ device with a thrombolytic agent to unblock 5 AVGs and 12 AVFs in 17 patients. All procedures were performed in the Interventional Nephrology Suite at SGH under local anaesthesia.

Patients with ESRD presenting with a thrombosed AVG or AVF were screened for eligibility. The preoperative diagnosis of a thrombosed non-functioning AVF/AVG was established clinically based on a lack of thrill or bruit or a duplex dependent diagnosis and the inability to have hemodialysis. Eligible patients were offered participation. All participants received an explanation of the potential benefits and risks of PMT using the Cleaner XT™ device before giving informed consent.

Inclusion criteria:
- Age 21–85 years
- Thrombosed AVG/AVF in the arm

Exclusion criteria:
- Patient unable to provide informed consent
- Sepsis or active infection
- Recent intracranial bleed or gastrointestinal bleed within the past three months
- Allergy to iodinated contrast media, antiplatelet drugs, heparin
- Pregnancy
- Life expectancy <12 months based on physician’s estimate

Data were collected from the electronic records and stored on a password protected Excel database (Microsoft Excel 2010, Redmond, WA, USA). Data on demographics, procedural aspects, technical success, patency rates and complications were documented. Longer-term patency rates (>6 months) were not available at the time of writing the manuscript.

Device

The Cleaner XT™ Rotational Thrombectomy System is percutaneous, 6Fr and catheter-based; it consists of a rotator drive unit attached to a sinuous-shaped radio-opaque wire. The drive unit rotates at approximately 4000 RPM, facilitating gentle mechanical declotting of occluded native vessel dialysis fistulae and synthetic dialysis access grafts. The Cleaner XT™ device was curated for smaller lumen vessels to allow easier manipulation and effective clot maceration.

Procedure technique

The procedure was performed according to our previously described centre protocol. Briefly, antegrade and retrograde vascular sheaths/cannulae were placed in the thrombosed AVG/AVF under ultrasound guidance. The thrombolytic agent choices and doses were at the operator’s discretion. Via the sheaths/cannulae, 2–6 mg of recombinant tissue plasminogen activator (r-TPA) was instilled directly into the thrombosed segment of the access. When the operator chose urokinase, the occlusions were crossed with a glide wire and angiographic catheter antegrade. A central venogram was performed, followed by a pullback venogram. Urokinase diluted in 10,000 unit/mL concentration was then administered along with the thrombus via the angiographic catheter or thrombolytic catheter. Balloon angioplasty was then performed to
treat the underlying culprit stenosis and macerate the clot. The arterial inflow was swept to clear the arterial plug at the arteriovenous or arterio-graft anastomosis using a 5.5Fr over-the-wire Fogarty balloon (Fig. 1). In the presence of residual thrombus, the Cleaner XT™ device was used for mechanical thrombectomy (Fig. 2). The device was introduced as many times as required to clear the residual clot (usually 2–3 times depending on the clot burden and adherence). The culprit stenotic lesions were either dilated with high-pressure balloons or stented, depending on recoil/dissection and location of the culprit lesions. Completion angiography was then performed to document flow restoration (Fig. 3).

Definitions

The outcomes conformed to the practice guidelines published by the Society of Interventional Radiology (SIR). The technical success was defined as restoration of flow with <30% residual stenosis on completion angiogram, while clinical success was considered the resumption of normal dialysis for at least one session. Procedural success was achieved if both criteria were met.

Primary patency was defined as the uninterrupted patency after intervention until the next access thrombosis and/or reintervention. Secondary patency was defined as patency after intervention until the access was surgically declotted, revised, or abandoned.

Complications were classified according to the American Society of Diagnostic and Interventional Nephrology system, with the severity increasing from Grade 1 to Grade 4. Grade 1 complications were defined as those requiring nominal therapy, with an unplanned increase in the level of care but no adverse clinical consequences or sequelae. Grade 2 complications required minor treatment, such as percutaneous therapy, but were managed successfully with no significant chronic sequelae afterwards. The complications were also compared to the SIR classification, where major complications included those requiring therapy and hospitalisation, permanent adverse sequelae and/or death and minor complications included overnight hospitalisation stay for observation only.

Statistical analysis

Descriptive statistics are presented as proportions or means (± standard deviation) for categorical and continuous data, respectively. Comparison of technical and clinical success and primary and secondary patency rates was made by Fisher’s exact test. A p-value of <0.05 indicated a statistically significant difference. The analysis was performed using SPSS software (IBM, New York, NY, USA, v. 25, 2017).

Results

A total of 17 procedures were performed on 17 patients. All patients had ESRD on haemodialysis. Baseline demographics are summarised in Table 1.

Both technical and clinical success were achieved in 88% (n = 15) of the patients. Of the two unsuccessful cases, one was due to the patient’s inability to tolerate the procedure, so the patient underwent an AVF later. The other unsuccessful case is currently using a long-term dialysis catheter to create a new AVF.

There were no major perioperative complications. Vein rupture occurred in 18% (n = 3) of the cases, but this did not involve the loss of the circuit. One of the patients became restless; thus, the procedure was abandoned in favour of creating a new AVF. The other two patients were treated initially with prolonged balloon tamponade; one case did not respond and required bailout stenting. These were classified as grade 2 complications. The other two cases of grade 1 complications were that of phlebitis...
and access site haematoma, which resolved with nominal therapy.

The mean primary patency time was 114 (± 116) days. There was a 65% one-month and 47% three-month primary patency rate, respectively, with an 83% one-month and 67% three-month primary patency rate in AVFs and a 20% one-month and 0% three-month primary patency rate in AVGs. The mean secondary patency time was 155 (± 132) days, with a 76% one-month and 65% three-month secondary patency rate, respectively. There was an 83% one-month and three-month secondary patency rate in AVFs and a 60% one-month and 20% three-month secondary patency rate in AVGs.

### Table 1 Baseline demographics

| Characteristic                                      | Number (%) or mean (± SD) or median (range) |
|-----------------------------------------------------|---------------------------------------------|
| Total procedures                                    | 17                                          |
| Gender                                              |                                             |
| Male                                                | 8                                           |
| Female                                              | 9                                           |
| Patient age (years)                                 | 66 (± 5.7)                                  |
| Comorbidities                                       |                                             |
| Diabetes mellitus                                   | 10 (58.8%)                                  |
| Ischaemic heart disease                             | 7 (41.2%)                                   |
| Chronic lung disease                                | 2 (11.8%)                                   |
| Cerebrovascular disease                             | 3 (17.6%)                                   |
| Cancer                                              | 3 (17.6%)                                   |
| Biochemical data on admission                       |                                             |
| Potassium                                           | 4.38 mmol/L (±0.479)                        |
| Urea                                                | 19.0 mmol/L (± 8.52)                        |
| Creatinine                                          | 751 mmol/L (±286)                           |
| Haemoglobin                                          | 11.2 g/dL (± 1.42)                          |
| Calcium                                             | 2.29 mmol/L (± 0.13)                        |
| Phosphate                                           | 1.52 mmol/L (± 0.46)                        |
| Albumin                                             | 36.3 g/L (±2.92)                            |
| HD access type                                       |                                             |
| AVG                                                 | 5                                           |
| AVF                                                 | 12                                          |
| Arteriovenous access age (days)                     |                                             |
| AVFs and AVGs                                       | 1425 (44 to 3488)                           |
| AVFs                                                | 1835.8 (664 to 4404)                        |
| AVGs                                                | 364 (33 to 1785)                            |
| Location of access                                  |                                             |
| AVF                                                 |                                             |
| Brachiocephalic                                     | 10                                          |
| Brachio-basilic                                     | 1                                           |
| Radio-ccephalic                                     | 1                                           |
| AVG                                                 |                                             |
| Brachio-axillary                                    | 1                                           |
| Brachiocephalic                                     | 1                                           |
| Brachio-basilic                                     | 3                                           |
| Previous complications                              |                                             |
| Stenosis                                            | 9                                           |
| Haematoma                                           | 3                                           |
| Infection                                           | 1                                           |
| Aneurysm                                            | 1                                           |
| Patients with previous intervention following access blockage prior to PMT | 11                                          |
| Time to intervention following access blockage      | 26 (6 to 151) hours                         |
| Local anaesthetic                                   | 1% lignocaine                               |
|                                                     | 15 (Mean 3.77 mL ± 2.39)                    |
| Not recorded                                        | 2                                           |
| Location of blockage                                |                                             |
| Juxta-anastomotic segment                           | 3                                           |
| Venous outflow                                      | 8                                           |
| Cephalic arch                                       | 5                                           |
| Intercannulation segment                            | 4                                           |
| Vein-graft junction                                 | 2                                           |
| Thrombolytic agent                                  |                                             |
| Urokinase                                           | 7 (Median 90 000 U)                         |
| Tissue plasminogen activator                       | 9 (Median 4 mg)                             |
| Not recorded                                        | 2                                           |
| Complications                                       |                                             |
| Grade 1                                             | 2                                           |
| Grade 2                                             | 2                                           |
| Time to cannulation                                 | 0.353 (± 0.493) days                       |
| Post-operative antiplatelet/anticoagulation         |                                             |
| Enoxaparin                                          | 6 (35.3%)                                   |
| DAPT                                                | 4 (23.5%)                                   |
| Aspirin only                                        | 1 (5.88%)                                   |
| Clopidogrel only                                    | 2 (11.8%)                                   |
| Warfarin                                            | 1 (5.88%)                                   |
| None                                                | 3 (2 failed procedures, 1 palliative care)  |

DAPT: dual antiplatelet therapy; SD: standard deviation; HD: haemodialysis; AVG: arteriovenous graft; AVF: arteriovenous fistula; PMT: pharmacomechanical thrombolysis
secondary patency rate in AVGs. One of the patients who experienced technical and clinical success with this procedure subsequently opted for palliative treatment the day after the procedure (Fig. 4).

Two patients had more than 72 h time to intervention. When these were excluded from the analysis, there was a 73% one-month and 53% three-month primary patency rate, with an 83% one-month and 73% three-month primary patency rate in AVFs and a 25% one-month and 0% three-month primary patency rate in AVGs. There was an 87% one-month and 73% three-month secondary patency rate, respectively, with a 91% one-month and three-month secondary patency rate in AVFs and a 75% one-month and 25% three-month secondary patency rate in AVGs.

Discussion

Pharmacomechanical thrombolysis is a relatively simple, minimally invasive procedure that can facilitate the rapid removal of clot under local anaesthesia. This potentially reduces surgical exposure, cost, treatment time, and intensive care unit stay compared to surgical thrombectomy. However, it also risks incomplete clot clearance and possible vessel injury. In various studies, PMT has been shown to be an effective technique comparable to surgical thrombectomy in the treatment of thrombosis in arteriovenous fistulas and grafts with similar procedural success, patency, and complication rates (Table 2).

PMT has also been shown to be comparable to CDT in the setting of deep vein thromboses in terms of patency rate, with a shorter length of stay leading to lesser costs. For most studies, the drugs used in PMT are either TPA and/or urokinase. They are similarly effective in the pharmacomechanical thrombolysis of AVFs. However, the type of thrombolysis agent did not lead to a significant difference in primary or secondary patency rates.

A study comparing hydrodynamic recirculation devices (Angiojet rheolytic system, Boston Scientific, Marlborough, MA, USA) to rotational recirculation devices (Arrow–Trerotola percutaneous thrombectomy device, Teleflex, Wayne, PA, USA) showed a higher clinical success and secondary patency rate in the device with a rotational mechanism. This might be due to the differences in the mechanism of action since the Venturi effect from hydrodynamic recirculation devices could potentially leave residual thrombus adherent to the wall. The percutaneous thrombectomy device had better contact with the thrombus through mechanical fragmentation and stripping, which resulted in a greater success rate. Examples of such devices include the ClariVein catheter, the Arrow–Trerotola device, and the Cleaner XT™ device. Two patients had more than 72 h time to intervention. When these were excluded from the analysis, there was a 73% one-month and 53% three-month primary patency rate, with an 83% one-month and 73% three-month primary patency rate in AVFs and a 25% one-month and 0% three-month primary patency rate in AVGs. There was an 87% one-month and 73% three-month secondary patency rate, respectively, with a 91% one-month and three-month secondary patency rate in AVFs and a 75% one-month and 25% three-month secondary patency rate in AVGs.

![Fig. 4 Combined Kaplan–Meier curve for patency.](image-url)
in stenotic regions, helping to predict the need for balloon angioplasty even before angiography.\(^{27}\) The comparable clinical success, patency and low complication rates reported herein also indicate that using the Cleaner XT™ device in thrombosed access grafts and fistulas is relatively safe and effective.

The KDOQI Vascular Access Guidelines\(^ {1}\) recommend that reasonable goals for graft patency would include a clinical success rate of >85% and three-month primary patency of 40%. In our study, the overall clinical success rate (88%) and three-month primary patency rate (65%) have met the KDOQI standards. Our study limitations include small sample size and a short follow-up period (at the time of data collection, most of the cases were less than one year post-procedure). A more extensive sample size and a longer follow-up time would be useful for further evaluation of the device as a PMT method. However, the immediate results of re-establishing flow and use of the access circuit for haemodialysis are excellent.

**Procedural tips and suggestions**

The Cleaner XT™ wall contact thrombectomy device is especially useful during endovascular salvage of thrombosed AVF and AVG with aneurysmal segments because angioplasty balloons cannot make good contact with the vessel wall for clot maceration in the presence of aneurysmal dilatation. Significant residual thrombus frequently remains within the aneurysmal segment and will fall back into the vessel lumen after deflation of the balloons. It is critical to compress the aneurysmal segment with the fingers while applying the Cleaner XT™ device to allow good contact of the device with the residual thrombus in the aneurysmal segment. Alternatively, the aneurysmal segment can be compressed using an ultrasound probe to visualise the Cleaner XT™ device’s position within the segment. Since the Cleaner XT™ is not an over-the-wire device, supporting wires must be removed before applying the device. Therefore, adequate treatment of the culprit stenosis with re-establishment of partial blood flow is important before applying the Cleaner XT™. Any ruptures within the dialysis circuit should be excluded before applying the Cleaner XT™ device.

**Conclusion**

The Cleaner XT™ for PMT is a feasible method of treating thrombosed haemodialysis fistulas and grafts. It has a relatively high technical and clinical success and low complication rate. However, a longer follow-up prospective study is required to assess its true efficacy.
Disclosure Statement

All authors have no conflict of interest.

Additional Note

This study was accepted as a poster presentation at the Congress of the Asian Society for Vascular Surgery on 23 October 2019, Bali Nusa Dua Convention Center, Indonesia.

Author Contributions

Study conception: TYT, CST
Data collection: all authors
Analysis: KWSJH
Investigation: KWSJH, TYT, CST
Writing: KWSJH, TYT, CST
Critical review and revision: all authors
Final approval of the article: all authors
Accountability for all aspects of the work: all authors

References

1) Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48 Suppl 1: S176-247.
2) Masud A, Costanzo EJ, Zuckerman R, et al. The complications of vascular access in haemodialysis. Semin Thromb Hemost 2018; 44: 57-9.
3) Davies MG, Hicks TD, Haidar GM, et al. Outcomes of intervention for cephalic arch stenosis in brachiocephalic arteriovenous fistulas. J Vasc Surg 2017; 66: 1504-10.
4) Inston N, Al Shakarchi J, Khawaja A, et al. Maintaining patency of vascular access for haemodialysis. Cardiovasc Eng Technol 2017; 8: 240-3.
5) Wang J, Chaikof EL. Chapter 12. Percutaneous thrombectomy and mechanical thrombolysis catheters. In: Moore WS, Ahn SS eds. Endovascular Surgery (4th Edition). Phila: Elsevier, 2011: 117-27.
6) Bush RL, Lin PH, Lumsden AB. Management of thrombosed dialysis access: thrombectomy versus thrombolysis. Semin Vasc Surg 2004; 17: 32-9.
7) Hong sakul K, Rookkapan S, Sungsiri J, et al. Pharmacomechanical thrombolysis versus surgical thrombectomy for the treatment of thrombosed haemodialysis grafts. Ann Acad Med Singapore 2015; 44: 66-70.
8) Mahmoud O, Vikatmaa P, Räsänen J, et al. Catheter-directed thrombolysis versus pharmacomechanical thrombectomy for upper extremity deep venous thrombosis: a cost-effectiveness analysis. Ann Vasc Surg 2018; 51: 246-53.
9) Morgan R, Belli AM. Percutaneous thrombectomy: a review. Eur Radiol 2002; 12: 205-17.
10) Lajvardi A, Trerotola SO, Strandberg JD, et al. Evaluation of venous injury caused by a percutaneous mechanical thrombolytic device. Cardiovasc Intervent Radiol 1995; 18: 172-8.
11) Cleaner XT™ rotational thrombectomy system directions for use. Athens, TX: Argon Medical Devices, Inc.
12) Cleaner rotational thrombectomy system, argon medical, 2018. Accessed August 2019. https://www.argonmedical.com/products/cleaner-rotational-thrombectomy-system.
13) Tan RY, Pang SC, Teh SP, et al. Comparison of alteplase and urokinase for pharmacomechanical thrombolysis of clotted hemodialysis access. J Vasc Access 2019; 20: 501-6.
14) Tan RY, Pang SC, Teh SP, et al. Outcomes of endovascular salvage of clotted arteriovenous access and predictors of patency after thrombectomy. J Vasc Surg 2020; 71: 1333-9.
15) Aruny JE, Lewis CA, Cardella JF, et al. Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access. Standards of Practice Committee of the Society of Cardiovascular & Interventional Radiology. J Vasc Interv Radiol 1999; 10: 491-8.
16) Vesely TM, Beathard G, Ash S, et al. Classification of complications associated with hemodialysis vascular access procedures. A position statement from the American Society of Diagnostic and Interventional Nephrology. J Vasc Access 2008; 9: 12-9.
17) Sacks D, Marinelli DL, Martin LG, et al. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol 2003; 14: S395-404.
18) Yang CC, Yang CW, Wen SC, et al. Comparisons of clinical outcomes for thrombectomy devices with different mechanisms in hemodialysis arteriovenous fistulas. Catheter Cardiovasc Interv 2012; 80: 1033-41.
19) Lim D, Ho DC, Chen L, et al. Novel use of the ClariVein catheter for pharmacomechanical thrombolysis of thrombosed haemodialysis grafts: a case series. J Vasc Access 2017; 18: 508-14.
20) Koksoy C, Yilmaz MF, Bosphog HS, et al. Pharmacomechanical thrombolysis of symptomatic acute and subacute deep vein thrombosis with a rotational thrombectomy device. J Vasc Interv Radiol 2014; 25: 1895-900.
21) Mueller RL, Raines JK. ClariVein mechanochemical ablation: background and procedural details. Vasc Endovascular Surg 2013; 47: 195-206.
22) Clarivein OC. Infusion catheter, vascular insights 2016. Accessed October 2019. https://clarivein.com/clarivein-ous/.
23) Sarac TP, Hilleman D, Arko FR, et al. Clinical and economic evaluation of the Trellis Thrombectomy Device for arterial occlusions: preliminary analysis. J Vasc Surg 2004; 39: 556-9.
24) Hilleman DE, Razavi MK. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis. J Vasc Interv Radiol 2008; 19: 377-83.
25) Vega F. 2010 Safety Comparison of Cleaner TM Rotational Thrombectomy System versus Arrow PTDTM in Native Vessel. San Carlos, CA: Isis Services, LLC.
26) Bozkurt A, Kirbaş İ, Kösehan D, et al. Pharmacomechanical thrombectomy in the management of deep vein thrombosis using the cleaner device: an initial single-center experience. Ann Vasc Surg 2015; 29: 670-4.
27) Ross J, Franga DL. Rotational thrombectomy of prosthetic haemodialysis arteriovenous grafts: 29 cases. Vein Magazine, 2014.